Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) have been assigned a consensus rating of “Moderate Buy” from the fourteen ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $27.77.

A number of equities research analysts have commented on TVTX shares. Evercore ISI increased their price objective on shares of Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Canaccord Genuity Group increased their target price on shares of Travere Therapeutics from $22.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, February 12th. Barclays increased their price target on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Wells Fargo & Company upgraded shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $9.00 to $27.00 in a research note on Monday, October 21st. Finally, HC Wainwright raised their target price on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, January 15th.

Insider Buying and Selling at Travere Therapeutics

In other news, CAO Sandra Calvin sold 12,090 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $18.30, for a total transaction of $221,247.00. Following the transaction, the chief accounting officer now directly owns 54,927 shares of the company’s stock, valued at approximately $1,005,164.10. The trade was a 18.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP William E. Rote sold 2,437 shares of the business’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total transaction of $47,424.02. Following the sale, the senior vice president now owns 83,170 shares of the company’s stock, valued at approximately $1,618,488.20. The trade was a 2.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 218,425 shares of company stock valued at $4,674,259 over the last ninety days. Corporate insiders own 3.75% of the company’s stock.

Hedge Funds Weigh In On Travere Therapeutics

Several institutional investors have recently modified their holdings of TVTX. Summit Investment Advisors Inc. lifted its holdings in Travere Therapeutics by 9.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,905 shares of the company’s stock worth $138,000 after purchasing an additional 667 shares during the period. Creative Planning lifted its holdings in Travere Therapeutics by 4.3% in the 3rd quarter. Creative Planning now owns 23,938 shares of the company’s stock valued at $335,000 after acquiring an additional 995 shares during the last quarter. Sterling Capital Management LLC lifted its holdings in Travere Therapeutics by 859.8% in the 4th quarter. Sterling Capital Management LLC now owns 2,361 shares of the company’s stock valued at $41,000 after acquiring an additional 2,115 shares during the last quarter. Rhumbline Advisers lifted its holdings in Travere Therapeutics by 2.2% in the 4th quarter. Rhumbline Advisers now owns 121,248 shares of the company’s stock valued at $2,112,000 after acquiring an additional 2,640 shares during the last quarter. Finally, Arizona State Retirement System lifted its holdings in Travere Therapeutics by 13.5% in the 4th quarter. Arizona State Retirement System now owns 22,396 shares of the company’s stock valued at $390,000 after acquiring an additional 2,666 shares during the last quarter.

Travere Therapeutics Price Performance

Travere Therapeutics stock opened at $22.91 on Tuesday. The firm has a market cap of $1.79 billion, a PE ratio of -5.04 and a beta of 0.72. Travere Therapeutics has a 52-week low of $5.12 and a 52-week high of $25.29. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96. The company’s 50 day moving average is $19.30 and its two-hundred day moving average is $16.29.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.